NASP 2024

Join Orsini’s Sessions at NASP 2024

Join Orsini experts Kathi Henson and Lynda Parker at NASP 2024 to learn more about the cell and gene therapy patient journey and the state of Duchenne muscular dystrophy care. You won’t want to miss these insightful presentations, so don’t forget to add them to your schedule!

The Patient Journey: Cell and Gene Therapies

Date: Oct. 6, 2024
Time: 9:05-9:55am CT
Orsini Panelist: Kathi Henson

The panel will also include representatives from Cencora, Nebraska Medicine, and OutcomeRx.

Cell and Gene Therapy Operational and Implementation Considerations for Specialty Pharmacy

Date: Oct. 6, 2024
Time: 1-1:50pm CT
Orsini Panelist: Kathi Henson

The panel will also include representatives from Cencora, Nebraska Medicine, OutcomeRx, and Vaalia Health.

Excellence in Rare Diseases

Date: Oct. 9, 2024
Time: 10:30-11:30am CT
Orsini Panelist: Nick Calla

The panel will also include representatives from URAC, UVA Health, the Medical University South Carolina Hospital Authority, and PANTHERx Rare Pharmacy.

Patients with rare diseases need care beyond what takes place only in a provider’s office. They may need extra assistance at home or getting to appointments or more specific information about their disease state and treatment protocols. And their needs can only be met by organizations that can deliver the highest level of care. In this session, URAC’s Director of Pharmacy will interview a panel of experts to discuss trends in rare disease pharmacy management. You’ll hear from members of URAC’s pharmacy review team and experts who provide rare disease patient care in their pharmacies. These leaders will share their insights on the future of caring for those with rare diseases, different examples of pharmacy models that provide rare disease patient care and what it means to understand the patient journey.

State of Care: Duchenne Muscular Dystrophy

Date: Oct. 9, 2024
Time: 12:30-1:30pm CT
Presenters: Kathi Henson and Lynda Parker

The Duchenne muscular dystrophy marketplace has seen tremendous growth and change in recent years, and new advances continue to be made and new therapies approved. In tandem with these changes, the care and management of Duchenne patients has evolved as well, and specialty pharmacies must shift to meet their unique needs. This session will offer an overview of the Duchenne market, discuss innovative approaches treating and supporting to Duchenne patients, and give insights on how specialty pharmacies can manage Duchenne therapies and maintain healthy relationships with their manufacturers.